BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 24240707)

  • 1. De-oncogenic HPV E6/E7 vaccine gets enhanced antigenicity and promotes tumoricidal synergy with cisplatin.
    Chen S; Liao C; Lai Y; Fan Y; Lu G; Wang H; Zhang X; Lin MC; Leng S; Kung HF
    Acta Biochim Biophys Sin (Shanghai); 2014 Jan; 46(1):6-14. PubMed ID: 24240707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The development of a novel cancer immunotherapeutic platform using tumor-targeting mesenchymal stem cells and a protein vaccine.
    Wei HJ; Wu AT; Hsu CH; Lin YP; Cheng WF; Su CH; Chiu WT; Whang-Peng J; Douglas FL; Deng WP
    Mol Ther; 2011 Dec; 19(12):2249-57. PubMed ID: 21792181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fusion protein vaccine by domains of bacterial exotoxin linked with a tumor antigen generates potent immunologic responses and antitumor effects.
    Liao CW; Chen CA; Lee CN; Su YN; Chang MC; Syu MH; Hsieh CY; Cheng WF
    Cancer Res; 2005 Oct; 65(19):9089-98. PubMed ID: 16204084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fusion protein vaccines targeting two tumor antigens generate synergistic anti-tumor effects.
    Cheng WF; Chang MC; Sun WZ; Jen YW; Liao CW; Chen YY; Chen CA
    PLoS One; 2013; 8(9):e71216. PubMed ID: 24058440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
    Peng S; Ferrall L; Gaillard S; Wang C; Chi WY; Huang CH; Roden RBS; Wu TC; Chang YN; Hung CF
    mBio; 2021 Jan; 12(1):. PubMed ID: 33468698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects.
    Lee SY; Kang TH; Knoff J; Huang Z; Soong RS; Alvarez RD; Hung CF; Wu TC
    Cancer Immunol Immunother; 2013 Jul; 62(7):1175-85. PubMed ID: 23615841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological protection against HPV16 E7-expressing human esophageal cancer cell challenge by a novel HPV16-E6/E7 fusion protein based-vaccine in a Hu-PBL-SCID mouse model.
    Lu Y; Zhang Z; Liu Q; Liu B; Song X; Wang M; Zhao X; Zhao Q
    Biol Pharm Bull; 2007 Jan; 30(1):150-6. PubMed ID: 17202676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors.
    Wieking BG; Vermeer DW; Spanos WC; Lee KM; Vermeer P; Lee WT; Xu Y; Gabitzsch ES; Balcaitis S; Balint JP; Jones FR; Lee JH
    Cancer Gene Ther; 2012 Oct; 19(10):667-74. PubMed ID: 22918471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.
    Li YL; Qiu XH; Shen C; Liu JN; Zhang J
    Oncol Rep; 2010 Nov; 24(5):1323-9. PubMed ID: 20878127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel therapeutic vaccine composed of a rearranged human papillomavirus type 16 E6/E7 fusion protein and Fms-like tyrosine kinase-3 ligand induces CD8
    Li J; Chen S; Ge J; Lu F; Ren S; Zhao Z; Pu X; Chen X; Sun J; Gu Y
    Vaccine; 2017 Nov; 35(47):6459-6467. PubMed ID: 29029939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
    Seo SH; Jin HT; Park SH; Youn JI; Sung YC
    Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control of Spontaneous HPV16 E6/E7 Expressing Oral Cancer in HLA-A2 (AAD) Transgenic Mice with Therapeutic HPV DNA Vaccine.
    Tseng SH; Liu L; Peng S; Kim J; Ferrall L; Hung CF; Wu T-
    J Biomed Sci; 2021 Sep; 28(1):63. PubMed ID: 34517865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen.
    Hung CF; Cheng WF; Hsu KF; Chai CY; He L; Ling M; Wu TC
    Cancer Res; 2001 May; 61(9):3698-703. PubMed ID: 11325841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical development of highly effective and safe DNA vaccines directed against HPV 16 E6 and E7.
    Oosterhuis K; Ohlschläger P; van den Berg JH; Toebes M; Gomez R; Schumacher TN; Haanen JB
    Int J Cancer; 2011 Jul; 129(2):397-406. PubMed ID: 21207427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrabodies targeting human papillomavirus 16 E6 and E7 oncoproteins for therapy of established HPV-associated tumors.
    Paolini F; Amici C; Carosi M; Bonomo C; Di Bonito P; Venuti A; Accardi L
    J Exp Clin Cancer Res; 2021 Jan; 40(1):37. PubMed ID: 33485370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens.
    Arribillaga L; Echeverria I; Belsue V; Gomez T; Lozano T; Casares N; Villanueva L; Domingos-Pereira S; Romero PJ; Nardelli-Haefliger D; Hervás-Stubbs S; Sarobe P; Rodriguez MJ; Carrascosa JL; Zürcher T; Lasarte JJ
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
    Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The synergistic therapeutic effect of cisplatin with Human papillomavirus E6/E7 short interfering RNA on cervical cancer cell lines in vitro and in vivo.
    Jung HS; Erkin OC; Kwon MJ; Kim SH; Jung JI; Oh YK; Her SW; Ju W; Choi YL; Song SY; Kim JK; Kim YD; Shim GY; Shin YK
    Int J Cancer; 2012 Apr; 130(8):1925-36. PubMed ID: 21630254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient expression of modified human papillomavirus 16 e6/e7 fusion protein and the antitumor efficacy in a mouse model.
    Zhou X; Qian X; Zhao Q; Lu Y; Xiong M
    Biol Pharm Bull; 2004 Mar; 27(3):303-7. PubMed ID: 14993792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPV-16 targeted DNA vaccine expression: The role of purification.
    Almeida AM; Tomás J; Pereira P; Queiroz JA; Sousa F; Sousa Â
    Biotechnol Prog; 2018 Mar; 34(2):546-551. PubMed ID: 29314780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.